giredestrant + atezolizumab

**Giredestrant + atezolizumab** is a combination of two investigational drugs used in clinical trials for ER-positive, HER2-negative locally advanced or metastatic breast cancer. - **Giredestrant** is a selective estrogen receptor degrader (SERD) and antagonist that acts by binding to the estrogen receptor (ER), blocking estrogen signaling, and promoting receptor degradation. Its mechanism can overcome resistance conferred by ESR1 mutations, and it is orally administered[1][2][3]. - **Atezolizumab** is a monoclonal antibody immune checkpoint inhibitor targeting PD-L1 to block its interaction with PD-1, thereby enhancing anti-tumor immune response. This combination aims to provide hormone blockade through giredestrant and immune activation via atezolizumab. The combination is being investigated for safety, tolerability, and efficacy, particularly in ER+/HER2− breast cancers, with trial data suggesting a trend toward improved overall response rates, especially in tumors with ESR1 mutations[4][5].

Other names

giredestrantatezolizumab